BlossomHill Therapeutics, Inc.’s Post

Gallium-68 (Ga-68) is a critical positron emission radioisotope used for PET imaging, usually obtained from a Ge-68/Ga-68 generator, and recently through a direct route using medical cyclotrons. Ga-68 is an essential component of prostate, ovarian and many other cancers diagnostic radiopharmaceuticals. Due to some challenges in obtaining the generator many teams have been using cyclotrons to produce Ga-68 directly and various Member States recommended initiation of an International Atomic Energy Agency (IAEA) Coordinated Research Project with the title of “Cyclotron production of Ga-68 radiopharmaceuticals (F22073)”. In order to transfer the latest achievements in the field especially within the framework of IAEA CRP, IAEA is holding a webinar with the title of “Production and quality control of cyclotron-based Ga-68 radiopharmaceuticals” on May 29th, 2024 for worldwide audience. Here is the link to register: https://lnkd.in/dRdxbeuT

Did you know that the Dept. of Defense funds medical research including therapeutics development and clinical trials? Check out the topics! White papers and LOIs due soon!

Are you attending the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Midwinter Meeting?   Mark your calendars for the Poster Session on Friday, February 2, 12:15-1:15 pm to join Dr. Thomas Hope from the University of California - San Francisco Medical Center (UCSF), one of the authors, as he presents a poster on ‘Prospective, multicenter, first in human phase 1/2 study of 64Cu PSMA I&T, investigating dosimetry, safety, and efficacy in men with biochemical recurrent metastatic prostate cancer’ from Curium’s Solar Trial.   Be a part of this informative session and gain insights into groundbreaking research! The Curium Clinical and Medical teams will be available in the Exhibit Hall throughout the meeting to answer questions about our ongoing clinical trials.   For more information visit: https://lnkd.in/daBXGJPC   #NuclearMedicine #NuclearImaging #SNMMI #NucMed #Radiopharmaceuticals #clinicaltrials #SNMMI2024 #Orlandoevents

[BLOG] Since many deregulations in ncRNAs expression and/or functions have been directly linked to a number of pathologies, ncRNAs became highly valuable targets for #DrugDiscovery. In this blog, Aurélien Tap and Christophe Parsy explain the existing ways for destabilizing or metabolizing RNAs, and how these mecanisms make progress the drug development. Read the blog here 👉 https://buff.ly/3AazVJc #RNA #MedChem #CRO#PROTAC

What can be learned from preclinical experiments? And what cannot be learned? What do preclinical researchers need to know about clinical applications? What do clinicians need to learn from preclinical researchers? Prof. Dr. Ken Herrmann (Universitätsmedizin Essen) and Prof. Dr. Katharina Lückerath (University Hospital Essen) will answer in "Theranostics: From Mice to Men and Back, a MOLECUBES Webinar" on Tuesday, 18 June 2024, 16:00 CEST (10:00 EDT). Register now: https://lnkd.in/d8H5Hi_F MOLECUBES NV #Theranostics #PreclinicalImaging #Imaging

What can be learned from preclinical experiments? And what cannot be learned? What do preclinical researchers need to know about clinical applications? What do clinicians need to learn from preclinical researchers? Prof. Dr. Ken Herrmann (Universitätsmedizin Essen) and Prof. Dr. Katharina Lückerath (University Hospital Essen) will answer in "Theranostics: From Mice to Men and Back, a MOLECUBES Webinar" on Tuesday, 18 June 2024, 16:00 CEST (10:00 EDT). Register now: https://lnkd.in/e5hfDYUZ MOLECUBES NV #Theranostics #PreclinicalImaging #Imaging

🚀 #EMIM 2024 Conference Launch Alert! 🚀 Join us at EMIM 2024 for our product launch! Stop by our booth to learn more and discuss your preclinical imaging needs. See you there! #EMIM2024 #ProductLaunch #PreclinicalImaging #pet #spect 🎉

A newly FDA-approved blood test, developed by the U.S. Army Medical Materiel Development Activity at Fort Detrick and Abbott can detect signs of traumatic brain injury more quickly than before. This groundbreaking device uses biomarkers discovered by Banyan Biomarkers, #OrigiGator and graduate of UF Innovate | Accelerate at Sid Martin Biotech. The i-STAT Alinity device analyzes blood samples to detect elevated levels of Banyan’s biomarkers, UCH-L1 and GFAP, indicating brain bleeds or injuries. If the biomarkers are detected, patients can be swiftly transported for further diagnosis and treatment. USAMMDA leads medical product development for the U.S. Army, while Abbott Point of Care, a division of Abbott Laboratories, collaborated on this project. The partnership with Banyan Biomarkers signifies a major advancement, as Abbott received licensure from Banyan in 2019 to integrate the company's biomarkers into the i-STAT Alinity device. Read more at: https://lnkd.in/eGeMEvDD

How promising is FAPI PET in breaking into a new frontier - pulmonary PET? Or other fibrogenic conditions? Among the few non-oncology applications of PET in development - granted it’s a poster. Key findings: • Higher uptake of FAPI compared to FDG in ILD patients. • Significant correlations between PET/CT parameters and clinical markers. • Quantitative FAPI PET showed potential in predicting PPF. https://lnkd.in/g7ndnSj6

Ali Sheikhani, CEO of Sheikhani Group, alongside Mohammad Naveed, Managing Director of Sheikhani Group, and Curt Kienest, COO of Mevion Medical Systems, are spearheading a groundbreaking initiative to bring the first proton therapy machine to Pakistan. The meeting, held in Boston, marks a significant step towards the integration of this cutting-edge can-cer treatment in the country's healthcare landscape. Proton therapy, a highly advanced form of radiation therapy, is renowned for its precision in targeting canc-erous and nonca-ncerous tumors. Unlike traditional X-ray radiation therapy, proton therapy minimizes damage to surrounding healthy tissue, thereby reducing side effects and potentially improving patient outcomes. The technology’s introduction to Pakistan aligns with the ongoing development of the JDC Shamim Sheikhani Free Can-cer Hospital, which has recently begun its first phase. This collaboration signifies a major milestone in Pakistan's fight against ca-ncer, promising a new era of hope and improved care for patients across the nation. @alisheikhani1